We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy
Evidence-based coverage of pharmaceutical development, regulatory affairs, and biotech innovation
Microgravity is increasingly recognised as a valuable tool for antimicrobial discovery due to its impact on microbial interactions, competition, and adaptation. Evidence from the International Space S
Read ArticleNHS England has widened abiraterone acetate access for adults with high-risk non-metastatic prostate cancer, with treatment expected to reach eligible patients within weeks. The change matters because
The NHS has entered a decisive phase in the use of pharmacogenomics, moving from targeted pilots to routine medicines optimisation informed by genetic data. By 2026, evidence from national implementat
The first regulatory approvals for a CRISPR-based medicine in the UK and EU marked a turning point for genomic medicine and set expectations for oncology. In 2023, the MHRA licensed exagamglogene auto
AI drug discovery shifts from promise to operational impact as pharma adopts risk-on posture amid tightening patent cliff timeline in 2026.
The United Kingdom enters 2026 as one of the most active environments in the world for high-paying clinical trials, particularly early phase studies involving healthy volunteers. Regulatory reforms, f
Cathepsin B (CTSB) is a lysosomal cysteine protease that plays a key role in protein turnover, antigen processing, and immune regulation. It is widely expressed across mammalian tissues. Recent resear
For over a century, the discovery of insulin transformed Type 1 Diabetes (T1D) from a fatal diagnosis into a survivable condition. Yet, despite remarkable technological advances, patients remain tethe
The human immune system is a complex network of cells, tissues, and signaling molecules that serves as a defense system. It continuously identifies and eliminates viruses, bacteria, abnormal cells, an
Chronic illness drives demand across the NHS and shapes budgets, workforce planning and service design. People living with multiple long-term conditions account for around half of hospital admissions,
Antimicrobial resistance is accelerating across health systems and undermining routine care. Surgical prophylaxis, oncology regimens and neonatal medicine all depend on reliable antibiotics, yet resis
For patients living with blood cancer or a severe blood disorder, a stem cell transplant is often the turning point between decline and recovery. Yet for years in the UK, the calendar has been the ene
Community pharmacy in the UK has entered a decisive phase. Policy, funding, and data infrastructure now point to a model where pharmacies act as clinical hubs for chronic disease management, preventio
Subscribe to our weekly pharmaceutical intelligence digest